Article info
PDFMigraine
Research paper
Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
- Correspondence to Dr Stephen D Silberstein, Jefferson Headache Center, 8130 Gibbon Building, 111 South 11th St., Philadelphia, PA 19107, USA; Stephen.Silberstein{at}jefferson.edu
Citation
Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT
Publication history
- Received October 31, 2013
- Revised September 24, 2014
- Accepted October 10, 2014
- First published December 12, 2014.
Online issue publication
April 13, 2016
Article Versions
- Previous version (13 April 2016).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/